Peer-reviewed veterinary case report
Serum interleukin-2 receptor levels in dogs with lymphoma
By Mizutani, Noriyuki et al.·Published in Veterinary immunology and immunopathology·2020·Department of Veterinary Internal Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
- Species:
- dog
Plain-English summary
A dog with lymphoma (a type of cancer affecting the lymph nodes) may have higher levels of a specific protein called soluble interleukin-2 receptor (sIL-2r) in their blood. Researchers found that dogs with high-grade B-cell lymphoma had significantly elevated sIL-2r levels compared to healthy dogs. This protein level can help veterinarians monitor the growth of the tumor and the effectiveness of treatment. By tracking changes in sIL-2r levels, vets can get a better idea of how well the dog is responding to therapy.
People also search for: dog lymphoma treatment · elevated sIL-2r in dogs · lymphoma prognosis in dogs
Abstract
Soluble interleukin-2 receptor (sIL-2r) is released directly from the surface of lymphocytes expressing interleukin-2 receptor alpha chain (CD25), and its serum concentration has been found to reflect the prognosis of human lymphoproliferative malignancies. In this study, we demonstrated the presence of sIL-2r in canine serum and developed a specific sandwich enzyme-linked immunosorbent assay (ELISA) to quantify the concentration of canine serum sIL-2r. In the immunoprecipitation (IP) assay, CD25 protein weighing approximately 45 kDa was detected in canine serum, smaller than the membrane-bound CD25 (approximately 55 kDa). To measure the concentration of serum sIL-2r in dogs, an ELISA system was developed. Serum sIL-2r levels were significantly higher in dogs with multicentric high-grade B-cell lymphoma before therapy than that in healthy dogs. Serum sIL-2r concentration was also found to be elevated in a proportion of dogs with other types of lymphoma. Changes in serum sIL-2r levels generally paralleled the changes in mass and lymph node size in dogs with high-grade B-cell lymphoma. This study demonstrated that serum sIL-2r level would be a marker to monitor tumour growth and regression in canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32434088/